FDA guidelines for relative risk of DDIs based on observed increases in AUC for the victim drug
| Category of Relative Risk | Observed Changes in AUC |
|---|---|
| Strong DDI | ≥5-fold increase in AUC |
| Moderate DDI | ≥2 but <5-fold increase in AUC |
| Weak DDI | ≥1.25 but <2-fold increase in AUC |